-
1 Comment
Zentalis Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 6.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Zentalis Pharmaceuticals, Inc gets an overall score of 2/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US98943L1070 |
Sector | Healthcare |
Industry | Biotechnology |
Beta | 1.61 |
---|---|
Market Cap | 101M |
PE Ratio | None |
Target Price | 6.3125 |
Dividend Yield | None |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ZNTL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025